Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-1406 · 1 trial · 1 indication
Blood samples will be collected at pre-specified timepoints to determine the AUC0-4w of MK-1406.
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.
Solicited injection-site reactions include tenderness, pain, redness/erythema, and swelling. Participants will record injection site reactions using a paper diary. The number of participants with solicited injection-site reactions will be reported.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study due to an AE will be reported.
| Arm | Type | Description |
|---|---|---|
| MK-1406 3-Injections | EXPERIMENTAL | Participants receive 3 subcutaneous (SQ) injections of MK-1406 on Day 1. |
| MK-1406 2-Injections | EXPERIMENTAL | Participants receive 2 SQ injections of MK-1406 on Day 1. |
| Name | Type | Description |
|---|---|---|
| MK-1406 | DRUG | Subcutaneous administration |
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Is in good health * Has body mass index (BMI) 18.0 to 32.0 kg/m\^2 Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * History of clinically significant en...
MK-1406 is an investigational small molecule being developed by Merck & Company, Inc. for use in healthy participants. It is currently in Phase 1 clinical development, with a single trial designed to evaluate its effects in healthy volunteers.
MK-1406 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting a Phase 1 clinical trial of this investigational small molecule in healthy participants.
MK-1406 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical testing in healthy participants.
MK-1406 is being studied in a single Phase 1 clinical trial with the identifier NCT07743151. This trial, titled "A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008)," is not yet recruiting and plans to enroll 400 healthy participants aged 18 years and older.
Yes, MK-1406 is being tested in healthy volunteers. The Phase 1 trial NCT07743151 is specifically designed for healthy participants, with an enrollment target of 400 individuals. The trial is controlled but not double-blinded.